Daiki Ikarashi

457 total citations
47 papers, 269 citations indexed

About

Daiki Ikarashi is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Daiki Ikarashi has authored 47 papers receiving a total of 269 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Surgery, 24 papers in Oncology and 22 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daiki Ikarashi's work include Bladder and Urothelial Cancer Treatments (19 papers), Cancer Immunotherapy and Biomarkers (19 papers) and Renal cell carcinoma treatment (11 papers). Daiki Ikarashi is often cited by papers focused on Bladder and Urothelial Cancer Treatments (19 papers), Cancer Immunotherapy and Biomarkers (19 papers) and Renal cell carcinoma treatment (11 papers). Daiki Ikarashi collaborates with scholars based in Japan, United States and Germany. Daiki Ikarashi's co-authors include Wataru Obara, Yoichiro Kato, Renpei Kato, Ryo Takata, Mitsugu Kanehira, Shigekatsu Maekawa, Tetsuya Nakatsura, Shigehisa Kitano, Takayuki Nakayama and Tamotsu Sugai and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Daiki Ikarashi

38 papers receiving 269 citations

Peers

Daiki Ikarashi
Arnab Basu United States
M.Á. Climent Spain
Hazel Lote United Kingdom
Lingfeng Meng China
Rana Harb United States
Young‐Jae Mok South Korea
Aleksander Ślusarczyk Poland
Toshihiko Yusa Japan
Sujay Vennam United States
Arnab Basu United States
Daiki Ikarashi
Citations per year, relative to Daiki Ikarashi Daiki Ikarashi (= 1×) peers Arnab Basu

Countries citing papers authored by Daiki Ikarashi

Since Specialization
Citations

This map shows the geographic impact of Daiki Ikarashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daiki Ikarashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daiki Ikarashi more than expected).

Fields of papers citing papers by Daiki Ikarashi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daiki Ikarashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daiki Ikarashi. The network helps show where Daiki Ikarashi may publish in the future.

Co-authorship network of co-authors of Daiki Ikarashi

This figure shows the co-authorship network connecting the top 25 collaborators of Daiki Ikarashi. A scholar is included among the top collaborators of Daiki Ikarashi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daiki Ikarashi. Daiki Ikarashi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Ikarashi, Daiki, Nozomi Hayakawa, Yuki Endo, et al.. (2025). Factors associated with primary resistance to enfortumab vedotin in previously treated patients with metastatic urothelial carcinoma: a multicenter retrospective study. International Journal of Clinical Oncology. 30(9). 1841–1848.
4.
Ikarashi, Daiki, et al.. (2025). Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs. Frontiers in Oncology. 14. 1493922–1493922. 1 indexed citations
5.
Hayakawa, Nozomi, Eiji Kikuchi, Ryo Yamashita, et al.. (2024). Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective study. Japanese Journal of Clinical Oncology. 54(11). 1194–1200. 7 indexed citations
6.
Ikarashi, Daiki, et al.. (2024). Parenchymal renal rupture due to an obstructive ureteric calculus in an incompletely duplicated renal pelvis and ureter. IJU Case Reports. 7(2). 177–180. 1 indexed citations
7.
Ikarashi, Daiki, Shigekatsu Maekawa, Renpei Kato, et al.. (2024). Changes in Renal Function After Nephroureterectomy for Upper Tract Urothelial Cancer in Elderly Patients. Cureus. 16(6). e61479–e61479. 1 indexed citations
8.
Ikarashi, Daiki, Shigehisa Kitano, Makiko Yamashita, et al.. (2024). Pathological complete response to neoadjuvant chemotherapy may improve antitumor immune response via reduction of regulatory T cells in muscle-invasive bladder cancer. Scientific Reports. 14(1). 1442–1442. 1 indexed citations
9.
10.
Abé, Masakazu, Noriyuki Sasaki, Akiko Yashima‐Abo, et al.. (2023). Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma. Cancer Science. 115(2). 529–539. 11 indexed citations
11.
12.
Kikuchi, Yoshinori, Hideaki Shimada, Yutaka Hatanaka, et al.. (2023). Clinical practice guidelines for molecular tumor markers, 2nd edition review part 1. International Journal of Clinical Oncology. 29(1). 1–19. 2 indexed citations
13.
Ikarashi, Daiki, et al.. (2022). Hyperprogressive disease after avelumab maintenance therapy in a patient with advanced ureter cancer: A case report. Urology Case Reports. 45. 102278–102278. 1 indexed citations
14.
Horimoto, Yoshiya, Daiki Ikarashi, Naotake Yanagisawa, et al.. (2022). High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs. Breast Cancer Research. 24(1). 67–67. 24 indexed citations
15.
Ikarashi, Daiki, Naoki Yanagawa, Masamichi Suzuki, et al.. (2022). Pathological Complete Response to Preoperative Nivolumab Plus Cabozantinib for Renal Cell Carcinoma With Inferior Vena Cava Thrombus: A Case Report. Cancer Diagnosis & Prognosis. 3(1). 124–129. 5 indexed citations
16.
Horimoto, Yoshiya, Daiki Ikarashi, Takayuki Nakayama, et al.. (2021). Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Research. 23(1). 99–99. 21 indexed citations
17.
Kato, Renpei, Daiki Ikarashi, Shigekatsu Maekawa, et al.. (2020). Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting. Translational Oncology. 13(6). 100771–100771. 4 indexed citations
18.
Ikarashi, Daiki, et al.. (2019). Complete response to perioperative treatment using nivolumab for metastatic renal cell carcinoma: A case report. Urology Case Reports. 24. 100839–100839. 6 indexed citations
19.
Ikarashi, Daiki, Yoichiro Kato, Mitsugu Kanehira, et al.. (2018). Appropriate preoperative membranous urethral length predicts recovery of urinary continence after robot-assisted laparoscopic prostatectomy. World Journal of Surgical Oncology. 16(1). 224–224. 21 indexed citations
20.
Ikarashi, Daiki, Kazuyuki Ishida, Masahiro Kashiwaba, et al.. (2017). Sporadic breast metastasis derived from renal cell carcinoma: A case report. Urology Case Reports. 16. 126–128. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arnab Basu Breakdown of academic impact, for papers by M.Á. Climent Breakdown of academic impact, for papers by Hazel Lote Breakdown of academic impact, for papers by Lingfeng Meng Breakdown of academic impact, for papers by Rana Harb Breakdown of academic impact, for papers by Young‐Jae Mok Breakdown of academic impact, for papers by Aleksander Ślusarczyk Breakdown of academic impact, for papers by Toshihiko Yusa Breakdown of academic impact, for papers by Sujay Vennam
Rankless by CCL
2026